BioStock: BrainCool’s CEO on FDA approval of Cooral

BrainCool has reached an important milestone in its oncology project with the product Cooral System. The company has now received market approval from the US Food and Drug Administration for counteracting chemotherapy-induced oral mucositis, a common and serious side effect of cancer treatment. BioStock contacted BrainCool’s CEO Martin Waleij for a comment on the significance of the FDA’s announcement.

Read the full interview with Martin Waleij at biostock.se:

https://www.biostock.se/en/2022/10/braincools-ceo-on-fda-approval-of-cooral/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/